David Peyok, DO
Addiction Medicine · Stilwell, OKNPI 1639530769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 310 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 48.8% of the total. 2025 is the largest year on record at $1,743, 2.5 times the $687 reported in 2022.
Across 310 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$504
- Johnson & Johnson$374
- Neurocrine Biosciences, Inc.$333
- Vanda Pharmaceuticals Inc.$266
- E.r. Squibb & Sons, L.L.C.$238
- plus $705 from 10 others
What the payments were for
- Food & beverage$4,47895%
- Education$2475%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 167 | $2,305 |
| Teva Pharmaceuticals USA, Inc. | 13 | $504 |
| Johnson & Johnson | 27 | $374 |
| Neurocrine Biosciences, Inc. | 28 | $333 |
| Vanda Pharmaceuticals Inc. | 23 | $266 |
| E.r. Squibb & Sons, L.L.C. | 12 | $238 |
| Otsuka America Pharmaceutical, Inc. | 11 | $202 |
| Alkermes, Inc. | 7 | $154 |
| AbbVie | 5 | $93 |
| Lilly USA, LLC | 4 | $56 |
| Mylan Specialty L.p. | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $53 |
| Indivior Inc. | 3 | $47 |
| Treace Medical Concepts, Inc. | 1 | $21 |
| Abiomed | 1 | $20 |
| Harmony Biosciences LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,725 in reported general payments places this provider in the 85th percentile of 20 addiction medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PerserisRisperidone | 129 | $365,415 |
| Invega SustennaPaliperidone Palmitate | 75 | $259,065 |
| FanaptIloperidone | 65 | $130,084 |
| CaplytaLumateperone Tosylate | 61 | $102,841 |
| Abilify MaintenaAripiprazole | 32 | $91,670 |
| Austedo XrDeutetrabenazine | 12 | $64,714 |
| LybalviOlanzapine/Samidorphan Malate | 38 | $51,041 |
| RexultiBrexpiprazole | 21 | $31,281 |
| VraylarCariprazine Hcl | 12 | $17,981 |
| Clozapine | 52 | $15,408 |
| XareltoRivaroxaban | 12 | $7,240 |
| Quetiapine Fumarate | 129 | $6,260 |
| Divalproex Sodium ErDivalproex Sodium | 61 | $5,387 |
| Olanzapine | 146 | $5,343 |
| Haloperidol Decanoate | 29 | $4,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Perseris | $47 | $365,415129 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $374 | $266,30587 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $266 | $130,08465 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $202 | $122,95153 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,305 | $102,84161 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $504 | $64,71412 claims |
| Alkermes, Inc.Lybalvi | $154 | $51,04138 claims |
| AbbVieVraylar | $93 | $17,98112 claims |
| Lilly USA, LLCOlanzapine | $56 | $5,343146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 20 addiction medicine providers in Oklahoma.
Other addiction medicine in Stilwell
- Gary DennyTulsa$6K
- Amanda ReedTulsa$6K
- Lowell RobertsonTulsa$2K
- Gayathri DasharathyOklahoma City$2K
- Lynn BaggettKonawa$976
- Dustin HayesBroken Arrow$735
- Bryan van DorenTulsa$613
- Dan CriswellDuncan$348
- Todd ReddingTulsa$220
- Jorg PahlOklahoma City$129
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.